Expert Review of Pharmacoeconomics & Outcomes Research
Volume 22, 2022 - Issue 6
Original Research
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Néboa Zozayaa Department of Health Economics, Weber, Madrid, Spain;b Department of Quantitative Methods in Economics and Management, University Las Palmas de Gran Canaria, Las Palmas, SpainCorrespondence[email protected]
https://orcid.org/0000-0003-4618-6894View further author information
https://orcid.org/0000-0003-4618-6894View further author information, , , , José Manuel Carrascosa Carrilloe Department of Dermatology, Germans Trias I Pujol University Hospital, Badalona, Spainhttps://orcid.org/0000-0003-4266-0771View further author information
https://orcid.org/0000-0003-4266-0771View further author information, , , Antonio García-Ruizh Health Economics and Rational Use of Medicines. Department of Pharmacology and Clinical Therapeutics, Biomedical Research Institute of Málaga (IBIMA), University of Málaga, Málaga, Spainhttps://orcid.org/0000-0001-6423-6993View further author information
https://orcid.org/0000-0001-6423-6993View further author information, , , , , Lluis Puigl Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spainhttps://orcid.org/0000-0001-6083-0952View further author information
https://orcid.org/0000-0001-6083-0952View further author information, & Álvaro HIdalgo-Vegan Weber Foundation, Madrid, Spain;o Department of Economic Analysis and Finances, University of Castilla-La Mancha, Toledo, Spainhttps://orcid.org/0000-0003-4088-8027View further author information
https://orcid.org/0000-0003-4088-8027View further author information show all